The effect of beta-blockers on the diagnostic accuracy of vasodilator pharmacologic SPECT myocardial perfusion imaging

Journal of Nuclear Cardiology

Volumn 16, Issue 3, 2009, Pages 358-367

  Yoon, Andrew J ^a   Melduni, Rowlens M ^b   Duncan, Shelly Ann ^a   Ostfeld, Robert J ^a   Travin, Mark I ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Beta blockers; Coronary artery disease; Myocardial perfusion imaging; Vasodilator stress

Indexed keywords

ADENOSINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPYRIDAMOLE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; DIAGNOSTIC AGENT; VASODILATOR AGENT;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FEMALE; HEART CATHETERIZATION; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; CLINICAL TRIAL; DRUG INTERACTION; EXERCISE TEST; HEART LEFT VENTRICLE FUNCTION; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING;

ADRENERGIC BETA-ANTAGONISTS; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 68049143204     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-009-9066-0     Document Type: Article

References (43)

1. Boucher CA, Brewster DC, Darling C, Okada RD, Strauss HW, Pohost GM. Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery. N Engl J Med 1985;312:389-94.
2. Young DZ, Guiney TE, McKusick KA, Okada RD, Strauss HW, Boucher CA. Unmasking potential myocardial ischemia with dipyridamole thallium imaging in patients with normal submaximal exercise thallium tests. Am J Noninvas Cardiol 1987;1:11-4.
3. Hendel RC, Layden JJ, Leppo JA. Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease. J Am Coll Cardiol 1990;15:109-16.
4. Iskandrian AS, Heo J, Nguyen T, Beer SG, Cave V, Ogilby JD, et al. Assessment of coronary artery disease using single-photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia. Am J Cardiol 1991;67:1190-4.
5. Iskandrian AS, Verani MS, Heo J. Pharmacologic stress testing: Mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol 1994;1:94-111.
6. Heller GV, Herman SD, Travin MI, Baron JI, Santos-Ocampo C, McClellan JR. Independent prognostic value of intravenous dipyridamole with technetium 99m tomography imaging in predicting cardiac events and cardiac-related hospital admissions. J Am Coll Cardiol 1995;26:1202-8.
7. Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al. Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995;2:3-17.
8. Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary artery disease: A meta-analysis. Am Heart J 2001;142:934-44.
9. Verani MS, Mahmarian JJ, Hixcon JB, Bayce TM, Staudacher RA. Diagnosis of coronary artery disease by vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 1990;82:80-7.
10. Iskandrian A. State of the art for pharmacologic imaging. In: Zaret BL, Beller G, editors. Nuclear cardiology: State of the art and future directions. 2nd ed. St. Louis: Mosby; 1998. p. 312-20.
11. Bridges A, Kennedy N, McNeill G. The effect of atenolol on dipyridamole 201Tl myocardial perfusion tomography in patients with coronary artery disease. Nucl Med Commun 1992;13:41-6.
12. Sharir T, Rabinowitz B, Livschitz S, Moalem I, Baron J, Kaplinsky E, et al. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. J Am Coll Cardiol 1998;31:1540-6.
13. Taillefer R, Ahlberg AW, Masood Y, White CM, Lamargese I, Mather JF, et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003;42:1475-83.
14. Boger LA, Volker LL, Hertenstein GK, Bateman TM. Best patient preparation before and during radionuclide myocardial perfusion imaging studies. J Nucl Cardiol 2006;13:98-110.
15. Baghdasarian SB, Heller GV. Patient preparation for nuclear imaging: When should anti-ischemic medications be withheld? J Nucl Cardiol 2007;14:775-81.
16. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;24:1350-8.
17. Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS. Stress protocols and tracers. J Nucl Cardiol 2006;13:e80-90.
18. URL: http://asnc.org/imageuploads/ImagingGuidelinesComplete062408.pdf. Last accessed date 10 July 2008.
19. Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick EH, Churchwell KB, et al. Myocardial perfusion and function: Single photon emission computed tomography. J Nucl Cardiol 2007;14:e39-60.
20. Berman DS, Abidov A, Kang X, Hayes SW, Friedman JD, Sclammarella MG, et al. Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion SPECT interpretation. J Nucl Cardiol 2004;11:414-23.
21. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su H, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138-47.
22. Mazzanti M, Germano G, Kiat H, Kavanagh PB, Alexanderson E, Friedman JD, et al. Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual-isotope myocardial perfusion SPECT. J Am Coll Cardiol 1996;27:1612-20.
23. Boucai L, Zonszein J. Effects of quality improvement strategies for type 2 diabetes in Bronx, NY. Clin Diabetes 2007;25:155-9.
24. URL: http://www.emerginghealthit.com/body.cfm?id=23. Last accessed date 5 December 2008.
25. URL: http://www.montefiore.org/guide/lookingglass/. Last accessed date 5 December 2008.
26. Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: Analysis of 461 patients. J Am Coll Cardiol 1989;14:1477-86.
27. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974;33:87-94.
28. Wilson RF. Assessing the severity of coronary artery stenosis. N Engl J Med 1996;334:1735-7.
29. Heller GV, Ahmed I, Tilkemeier PL, Barbour MM, Garber CE. Influence of exercise on the presence, distribution, and size of thallium-201 defects. Am Heart J 1992;123:909-16.
30. Bøttcher M, Refsgaard J, Madsen MM, Randsbaek F, Kaltoft A, Bøtker HE, et al. Effect of antianginal medication on resting myocardial perfusion and pharmacologically induced hyperemia. J Nucl Cardiol 2003;10:345-52.
31. Heusch G, Guth BD. Neurogenic regulation of coronary vasomotor tone. Eur Heart J 1989;10 Suppl F:6-14.
32. Second messenger systems. In: Clark WG, Brater DC, Johnson AR, editors. Goth's medical pharmacology. St. Louis, MO: Mosby Year Book; 1992. p. 13-7.
33. Gerson MC. Reduction in dipyridamole-induced single-photon emission computed tomography myocardial defect size by beta-blockers: Time to re-examine the patient preparation protocol for pharmacologic stress testing. J Am Coll Cardiol 2003;42:484-6.
34. Beller GA, Holzgrefe HH, Watson DD. Effects of dipyridamole-induced vasodilation on myocardial uptake and clearance kinetics of thallium-201. Circulation 1983;68:1328-38.
35. Kubota I, Ikeda K, Igarashi H, Kawashima S, Yamaki M, Yasumura S, et al. Inhibition of dipyridamole induced myocardial ischemia by diltiazem in patients with coronary artery disease. J Cardiovasc Pharmacol 1987;9:363-7.
36. Parkash R, deKemp RA, Ruddy TD, Kitsikis A, Hart R, Beauchesne L, et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 2004;11:440-9.
37. Marie PY, Mercennier X, Danchin N, Djaballah K, Grentzinger A, Zannad F, et al. Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with β-blockers. J Nucl Cardiol 2003;10:361-8.
38. Mehta D, Iskandrian AE. Effects of therapy with β-blocker agents on myocardial perfusion and outcome. J Nucl Cardiol 2003;10:429-32.
39. Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden. Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91.
40. Bonetti PO, Wilson SH, Rodriguez-Porcel M, Holmes DR, Lerman LO, Lerman A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 2002;40:546-54.
41. Mostaza JM, Gomez MV, Gallardo F, Salazar ML, Martín-Jadraque R, Plaza-Celemín L, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000;35:76-82.
42. Schwartz RG, Pearson TA, Kalaria VG, Mackin ML, Williford DJ, Awasthi A, et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol 2003;42:600-10.
43. Verna E, Ceriani L, Giovanella L, Binaghi G, Garancini S. False-positive" myocardial perfusion scintigraphy findings in patients with angiographically normal coronary arteries: Insights from intravascular sonography studies. J Nucl Med 2000;41:1935-40.